Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Preparing New Viagra TV Campaign

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer is understood to have produced at least one new ad, but it has not yet aired. The company may change its plans depending on what FDA does in response to other DTC ads in the erectile dysfunction category.

You may also be interested in...



FDA Planning Enforcement Response To DTC Ads Aired Last Weekend

Acting Commissioner Crawford has formed an "informal" task force to "see if there is a violation we can pursue." Erectile dysfunction ads are a particular sore point, Crawford indicates. Action could come before the end of the week.

Viagra "Wild Thing" Ads Too Wild For FDA; Pfizer Will Pull Them

FDA declares that the ads, featuring a man with blue horns, cross the line and cannot be considered unbranded "reminder" ads. Pfizer says it will discuss FDA's concerns before deciding whether and how to resume the campaign.

Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel